Alzheimer's Association Announces World's Alzheimer's Disease Experts to Showcase Latest Research The 9th International Conference on Alzheimer's Disease CHICAGO–(BUSINESS WIRE)–April 13, 2004–
The newest treatment advances in Alzheimer's disease and steps toward prevention will be on display at The 9th International Conference on Alzheimer's Disease and Related Disorders, July 17-22, 2004, at the Pennsylvania Convention Center in Philadelphia, Pa., USA. Presented by the Alzheimer's Association, the conference is the world's premiere forum for research advances in Alzheimer's disease.
"The Alzheimer's Association's goal of delaying the disabling symptoms and eventually preventing Alzheimer's is a feasible objective that we believe the research community can achieve in the next decade," said Sheldon Goldberg, Alzheimer's Association president and CEO. "The International Conference is the most important forum for introducing the latest discoveries in Alzheimer research. This is where world research leaders and all of us affected by this disease get to see the return on the international, and the Association's, investment in Alzheimer research."
The conference is expected to attract 5,000 researchers to share groundbreaking information on the causes of Alzheimer's, how it progresses, and ways it can be monitored and treated — plus possible strategies for slowing its progression and delaying or preventing its onset.
The Conference will explore:
— Treatment: Established and experimental therapies.
— Prevention: New hope for preventing dementia and delaying its onset.
— Who's at risk: Epidemiology and risk factors.
— Earlier intervention: Diagnosis and biomarkers; genetics and testing.
— Speeding new treatments: Neuropathology and imaging; models of the disease.
— Understanding the disease and managing symptoms: Brain/behavioral relationships; patient management and social-behavioral research.
— Ethical issues in dementia care.
Special Session Focuses on Imaging and Alzheimer's On Saturday, July 17, the Alzheimer's Imaging Consortium will hold a one-day meeting focusing on the use of all types of imaging (including MRI, PET, SPECT, CT, and others) for diagnosis, therapy, monitoring, early detection, and basic research.
— Premier Level Sponsor: Elan Corporation, plc
— Gold Level Sponsors: Forest Laboratories, Inc.; Janssen-Cilag
— Silver Level Sponsors: Eisai, Inc. and Pfizer Inc; Novartis Pharma AG; Beverly Enterprises
— Bronze Level Sponsor: AstraZeneca; Intel Corporation
Editors: Information on the 9th International Conference on Alzheimer's Disease and Related Disorders is available on the Alzheimer's Association's website at http://www.alz.org/internationalconference/home.html All news media must register for the conference. For more information and to register, contact: Alzheimer's Association, Media Relations Department, 312-335-4078, email@example.com